Hikma Pharmaceuticals PLC
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| HIK.L | 300584.SZ | HYPE3.SA | KNSA | 1795.TW | MRK.DE | |
|---|---|---|---|---|---|---|
| Market cap | 3.46B | 3.32B | 18.82B | 6.22B | 46.89B | 61.85B |
| P/E (TTM) | 12.8 | 74.7 | 10.1 | 80.5 | 12.4 | 26.1 |
| Forward P/E | 8.9 | 26.1 | 8.5 | 49.3 | 7.4 | 15.9 |
| Price/book | 1.9 | 3.1 | 1.3 | 9.5 | 2.0 | 2.0 |
| Dividend yield | 3.90% | 0.36% | 3.86% | — | 1.47% | 1.50% |
| 1-year change | −7.24% | −49.48% | +18.38% | +113.80% | −39.08% | +27.14% |
| Today | +1.21% | −1.88% | −1.87% | −4.17% | +0.57% | −2.83% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All HIK.L news ›Why Is Hikma Pharmaceuticals (LSE:HIK) Stock In Focus Today After Reiterating Its Outlook?
The update paints a picture of a business that is investing while still delivering profit growth. Management pointed to new product launches, a strengthened pipeline, fresh partnerships and manufacturing optimisation as the pillars of…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
kalkinemedia.com2
-
themarketsdaily.com1
-
tradingview.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.